56
NeuroOne Medical Technologies Corporation, a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has accelerated the anticipated timeline of its 510(k) submission to the FDA for trigeminal nerve ablation to May 2025, which leverages the Company’s patented OneRF Technology Platform. The Company had previously projected a submission by the end of June 2025.
Trigeminal nerve ablation is a minimally invasive surgical procedure that uses radiofrequency (RF) energy to destroy abnormal tissue to relieve severe, chronic pain in the face caused by trigeminal neuralgia. The trigeminal nerve is the main sensory nerve in the face and NeuroOne’s…